A detailed history of Morgan Stanley transactions in Sol Gel Technologies Ltd. stock. As of the latest transaction made, Morgan Stanley holds 65,809 shares of SLGL stock, worth $42,775. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,809
Previous 38,584 70.56%
Holding current value
$42,775
Previous $37,000 56.76%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.66 - $1.05 $17,968 - $28,586
27,225 Added 70.56%
65,809 $58,000
Q1 2024

Aug 16, 2024

BUY
$0.95 - $1.5 $9,166 - $14,473
9,649 Added 33.35%
38,584 $37,000
Q1 2024

May 15, 2024

BUY
$0.95 - $1.5 $9,166 - $14,473
9,649 Added 33.35%
38,584 $37,000
Q4 2023

Aug 16, 2024

SELL
$0.92 - $1.6 $33,924 - $58,998
-36,874 Reduced 56.03%
28,935 $31,000
Q4 2023

Feb 13, 2024

SELL
$0.92 - $1.6 $276 - $480
-300 Reduced 1.03%
28,935 $31,000
Q3 2023

Nov 15, 2023

SELL
$1.63 - $3.94 $5,959 - $14,404
-3,656 Reduced 11.12%
29,235 $47,000
Q2 2023

Aug 14, 2023

BUY
$2.99 - $4.15 $8,838 - $12,267
2,956 Added 9.87%
32,891 $98,000
Q1 2023

May 15, 2023

BUY
$3.44 - $5.32 $1,032 - $1,596
300 Added 1.01%
29,935 $116,000
Q4 2022

Feb 14, 2023

SELL
$4.26 - $5.22 $16,196 - $19,846
-3,802 Reduced 11.37%
29,635 $135,000
Q3 2022

Nov 14, 2022

SELL
$4.16 - $6.4 $14,551 - $22,387
-3,498 Reduced 9.47%
33,437 $167,000
Q2 2022

Oct 27, 2022

BUY
$4.1 - $7.36 $13,529 - $24,288
3,300 Added 9.81%
36,935 $151,000
Q2 2022

Aug 15, 2022

BUY
$4.1 - $7.36 $13,529 - $24,288
3,300 Added 9.81%
36,935 $151,000
Q1 2022

Oct 27, 2022

SELL
$6.64 - $8.21 $21,912 - $27,093
-3,300 Reduced 8.93%
33,635 $248,000
Q1 2022

May 13, 2022

SELL
$6.64 - $8.21 $5,976 - $7,389
-900 Reduced 2.61%
33,635 $248,000
Q4 2021

Feb 14, 2022

SELL
$6.57 - $9.78 $8,541 - $12,714
-1,300 Reduced 3.63%
34,535 $255,000
Q3 2021

Nov 15, 2021

BUY
$8.85 - $12.5 $317,139 - $447,937
35,835 New
35,835 $359,000

Others Institutions Holding SLGL

About Sol-Gel Technologies Ltd.


  • Ticker SLGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,129,500
  • Market Cap $15M
  • Description
  • Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...
More about SLGL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.